Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will ...
20h
Cancer's malignant remote control: How tumors reprogram liver fat metabolism to disarm immune cells
In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical ...
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, ...
New Study Advances cDC1-Based Cancer Immunotherapy / Akata Saha, Allison Dyevoich, Bhakti Patel, Btnl2 Protein, cancer, CD4 T, CD8+ T, Cellular ...
Faron Enrolls First Patient in BEXAR Trial of Bexmarilimab for Metastatic Soft-Tissue Sarcoma / BEXAR, Bexmarilimab, Clever-1 ...
A new iPSC-derived dendritic cell platform uses patient tumor material to prime T cells against multiple cancer targets.
The "Global VISTA Inhibitor Market Opportunities & Clinical Trials Insight 2026" has been added to ResearchAndMarkets.com's offering.Thereport delivers a consolidated view of market drivers, ...
Radiotherapy augments immunotherapy, yet conventional 2 Gy x-ray fractions largely induce apoptosis, whereas robust ...
Researchers in Purdue University's College of Pharmacy have developed and validated a new series of small-molecule inhibitors ...
Zhong-Yin Zhang leads a team that has developed and validated a novel series of small-molecule inhibitors that promote ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results